INTERIM REPORT

JUNE 30, 2025



UNAUDITED INTERIM FINANCIAL STATEMENTS

30 JUNE 2025







RESPONSIBILITY STATEMENT

AS AT 30 JUNE 2025

The Directors of Rapid Nutrition PLC and its controlled entity ("the Group") confirm that, to the best of our knowledge.

- a. The condensed set of consolidated financial statements have been prepared in accordance with IAS 34 "Interim Financial Reporting" and all relevant pronouncements of *the companies ACT 2006*
- b. The condensed set of consolidated financial statements give a true and fair view of the Group's financial position as at 30 June 2025 and of its performance for the interim period ended on that date.
- c. There are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

By order of the Board

Simon St Ledger

Simon St. Ledger

Managing Director



CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE PERIOD ENDED 30 JUNE 2025

	Note	Period ended June 2025 Unaudited AUD	Period ended June 2024 Unaudited AUD
Turnover	2	113,125	276,051
Cost of sales		(53,542)	(294,192)
Gross profit	_	59,583	(18,141)
Other income		(20,759)	(315)
Advertising and Marketing		(387,125)	(138,435)
Bank fee		(6,565)	(11,318)
Accounting fee		(75,568)	(175,735)
Selling and marketing expenses		(155,260)	(210,953)
Salaries and wages		(49,043)	(54,972)
Convertible bonds expenses		(470,628)	(776,449)
Legal expenses		(178,025)	-
Subscription		(111,236)	(86,604)
Rent		(40,523)	(52,788)
Interest expense		(6,017)	(249,230)
Administration expense	_	(209,680)	(211,227)
Operating profit/(loss)		(1,650,846)	(1,986,167)
Tax expense	_	-	
(Loss)/Profit for the period attributable to members of the			
Company	_	(1,650,846)	(1,986,167)
Other comprehensive income			
Exchange gains arising on translation on foreign operations	_	5,370	
Other comprehensive income for the year	_	5,370	
Total comprehensive income for the period attributable to	_		
members of the Company	_	(1,645,476)	(1,986,167)
Basic & diluted earnings per share	4	(0.0003)	(0.0004)

All of the activities of the Group are classed as continuing. All of the total comprehensive income for the period is attributable to the owners of the Group



CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2025

Assets Non-current assets	Note	June 2025 Unaudited	Dec 2024 AUD
Non-current assets		AUD	AUD
Investments	3	100	100
Property, plant and equipment Intangible assets		68,977	76,653
Total non-current assets		69,077	76,753
_		<u> </u>	<u> </u>
Current assets Trade and other receivables		893,423	448,691
Inventory		512,062	334,298
Cash and cash equivalents		900,672	95,809
Total current assets		2,306,157	878,798
Total assets		2,375,234	955,551
			· · · · · · · · · · · · · · · · · · ·
Non-current liabilities			
Tax and other related		-	-
Borrowings		78,157	78,157
Total non-current liabilities		78,157	78,157
Current liabilities			
Trade and other payables		640,268	486,062
Borrowings		4,930	9,925
Total current liabilities	_	645,198	495,987
Total liabilities		723,355	574,144
Net assets		1,651,879	381,407
Issued capital and reserves			_
Shares		45,928,353	42,964,727
Share premium		4,012,237	4,012,237
Merger reserve		(26,061,971)	(26,061,971)
Convertible notes		-	47,678
Retained earnings		(12,242,131)	(9,311,145)
Current year earning		(1,645,476)	(2,930,986)
Foreign exchange		75,430	75,430
Asset reserve		(8,414,563)	(8,414,563)
Total equity and reserves		1,651,879	381,407

These financial statements were approved and authorised for release by the Directors on 24 October 2025 and are signed on its behalf by:

S St Ledger

Managing Director

Simon St Ledger

Company registration number: 07905640



CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 30 JUNE 2025

	Ordinary Share Capital AUD	Share premium AUD	Merger Reserve AUD	Convertible Notes AUD	Retain Earnings AUD	Assets Reserve AUD	Foreign Exchange AUD	Total equity
Balance at 31 Dec 2023	39,065,638	4,012,237	(26,061,971)	674,573	(9,171,370)	(8,414,563)	75,838	180,382
Ordinary share capital, net of transaction costs	-	-	-	-	-	-	-	-
Loss for the year	-	-	-	-	(1,986,167)	-	-	(1,986,167)
Notes issued during the year	-	-	-	2,969,301	-	-	-	2,969,301
Transferred to equity	1,600,581			(1,600,581)	-	-	-	-
Foreign Exchange				_		-	(14,834)	(14,834)
Balance at 30 Jun 2024	40,666,219	4,012,237	(26,061,971)	2,043,293	(11,157,537)	(8,414,563)	61,004	1,148,682
	Ordinary Share Capital	Share premium	Merger Reserve	Convertible Notes	Retain Earnings	Assets Reserve	Foreign Exchange	Total equity
	AUD	AUD	AUD	AUD	AUD	AUD	AUD	AUD
Balance at 31 Dec 2024	42,964,728	4,012,237	(26,061,971)	47,678	(12,242,131)	(8,414,563)	75,430	381,407
Ordinary share capital, net of transaction costs	-	-	-	-	-	-	-	-
Loss for the year	-	-	-		(1,645,476)	-	-	(1,645,476)
Notes issued during the year	-	-	-	2,742,749	-	-		2,742,749
Transferred to equity	2,963,626	-	-	(2,790,427)	-	-	-	173,199
Foreign Exchange				-	-		-	
Balance at 30 Jun 2025	45,928,353	4,012,237	(26,061,971)	-	(13,887,607)	(8,414,563)	75,430	1,651,879





	Note June 202 Unaudite AUI	d Unaudited
Cash flows from operating activities		
Receipts from customers	(509,371) 511,621
Payments to suppliers and employees	(1,423,520	(2,687,259)
Net cash used from operating activities	(1,932,891) (2,175,638)
Cash flows from investing activities		
Other cash from investing activities		_
Net cash used in investing activities		
Cash flows from financing activities		
Proceeds from issue of shares		
Lease liability payments	(4,995	-
Proceeds from borrowings	2,742,74	9 2,712,861
Net cash used by financing activities	2,737,75	4 2,712,861
Increase/(decrease)in cash and cash equivalents	804,86	3 537,223
Cash and cash equivalents at the beginning of the yea	•	·
Cash and cash equivalents at the end of the year	900,67	_

MANAGEMENT REVIEW REPORT THE MEMBERS OF RAPID NUTRITION PLC FOR THE PERIOD ENDED 30 JUNE 2025



The consolidated financial statements and notes represent those of Rapid Nutrition PLC ('the Company') and its subsidiaries ("the consolidated group" or "group"), for the period under review to 30 June 2025.

1. General Information

The information for the period ended 30 June 2025 does not constitute statutory accounts as defined in section 434 of the Companies Act 2006. A copy of the statutory accounts for that period has been delivered to the Registrar of Companies. The consolidated financial statements and notes represent those of Rapid Nutrition PLC ('the Company') and its subsidiaries ("the consolidated group" or "group"), for the period ended 30 June 2025. With reference to the revised and re-issued annual audited Financial Statement for the year ended 31 December 2024 (in accordance with the IAS framework, in particular IFRS-IAS 9 and 18), were recognised in the second period of the financial year ended 31 December 2024. It should therefore be noted that the amounts presented in the comparable period have not been restated for these adjustments.

1.1 Accounting Policy

Basis of preparation

The statutory financial statements of the Group are prepared in accordance with IFRSs as adopted by the European Union. The condensed set of consolidated financial statements included in this interim financial report has been prepared in accordance with International Accounting Standard 34 'Interim Financial Reporting', as adopted by the European Union.

Going concern

This report has been prepared on the going concern basis, which contemplates the continuation of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business.

The Directors recognise that the ability of the Group to continue as a going concern and to pay its debts as and when they fall due may be dependent on settlement of substantial receivable balances, funding via equity and debt, continued support of shareholders through short term loans, and successful realisation of revenue growth via the company's plans for successful launch of company's new product lines. On this basis, the Directors believe there are sufficient funds to meet the Group's working capital requirements going forward.

The company's cash position has strengthened post 30 June 2025 due to a secured financing commitment to support growth and which has enabled the company to pay down all its debt commitments during the first half of the year.

The financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts nor to the amounts and classification of liabilities that may be necessary should the Group be unable to continue as a going concern.

Changes in accounting policy

For the current, interim financial period, the Group has noted no amendments to International Accounting Standards that will be effective for the first time. As such, the same accounting policies, presentation and methods of computation are followed in the condensed set of financial statements as applied in the Group's latest statutory audited financial statements.

Functional and presentation currency

An entity's functional currency is the currency of the primary economic environment in which it operates. Due to the importance of Australia as the group's base of operations, which includes but not limited to payroll, insurance, majority of cost of sale are incurred and where the board and senior management are based, the directors of the group view Australian Dollars as the group's functional currency. The Group uses Australian bank accounts and all dealings and commercial contracts are through the Australian company.

The financial information in this consolidated interim financial statements are in Australian dollars.



2. Revenue

	30 June 2025	30 June 2024
	AUD	AUD
Direct Sales	113,125	276,051

3. Investments

Adopted classification under IFRS 9

	30 June 2025	30 June 2024
	AUD	AUD
Investment in Vibe Life	100	100
	100	100

4. Earnings per share

The following reflects earnings and share data used in the earnings per share calculation.

	30 June 2025	30 June 2024
	AUD	AUD
(Loss)/Profit for the period	(1,645,476)	(1,986,167)
Number of shares	4,888,714,154	4,789,255,462
	(0.0003)	(0.0004)

There were convertible instruments and attached warrants in issue as at 30 June 2025 as disclosed on the company website where the company maintains an updated register, that if converted in full would result in the allotment of ordinary shares, calculated pursuant to the terms of the convertible instruments, which could potentially dilute earnings per share in the future.

5. Subsequent Events

- 29 July The Group published its half-year liquidity contract statement with TSAF Tradition Securities
 and Futures, in accordance with the framework authorized by Euronext Growth Paris.
- 12 August The Group announced the successful completion of a strategic upgrade to its e-commerce
 platform, now built on Shopify's latest architecture.
- 2 September Rapid Nutrition announced it had secured a Trademark License Agreement for Creapure®, widely regarded as the gold standard in creatine.

MANAGEMENT REVIEW REPORT THE MEMBERS OF RAPID NUTRITION PLOFOR THE PERIOD ENDED 30 JUNE 2025



Interim Management Report

For the Half-Year Ended 30 June 2025

Rapid Nutrition PLC is pleased to present its interim management report for the six-month period ended 30 June 2025.

Building Momentum for Scalable Growth

The first half of 2025 marked a decisive step forward for Rapid Nutrition, laying the commercial, operational, and financial foundation for the Company's next phase of growth. With strategic investments in product innovation, expanded production, market activation across Asia, and strengthened financial positioning, Rapid Nutrition has emerged from H1 with greater momentum, clarity, and capacity than ever before. Importantly, the decisions made and actions taken during this period are expected to materially flow through to revenue and market expansion in the second half of the year and beyond.

Headline revenue for the period was \$ 113,125, compared to \$ 276,051 in the same period last year. This reflects the Company's intentional transition away from one-off, lower-margin bulk sales toward a direct-to-consumer subscription model. While this approach naturally impacts near-term revenue, it establishes a more stable, predictable, and higher-quality earnings base for the future.

By June 30, the Company had secured 642 new active subscriptions, demonstrating the appeal of its customer-first strategy. Under this model, Rapid Nutrition invests upfront by shipping the first product free of charge — a move that has significantly increased conversions. Revenue recognition begins from the second month, with profitability achieved from month three onward. This approach strengthens long-term value and brand loyalty, creating a foundation for recurring and compounding growth.

At the same time, trade receivables increased to \$893,423 (vs. \$448,691 in H1 2024), representing orders already placed and due to be recognised in H2. On an accrual basis, this would reflect a stronger comparative performance than headline revenue suggests, underscoring robust underlying demand and commercial momentum.

Key Highlights - H1 2025

Financial Strengthening & Balance Sheet Improvements

- Cash position improved nearly 10x to \$ 900,672 (vs. \$ 95,809 at Dec 2024).
- Trade receivables increased to \$893,423 (vs. \$448,691 in H1 2024), providing a strong pipeline for H2 revenue recognition.
- Inventory and working capital expanded to support upcoming sales campaigns.
- Convertible debt fully cleared, eliminating dilution risk and strengthening shareholder value.
- Net assets rose to \$ 1.65 million, over 4x higher than the start of the year.
- Operating cash burn reduced by 11% YoY, reflecting tighter cost controls and efficiency.

Strategic Market Expansion

- China launch well underway via Douyin, with over 2,800 units sold in June despite limited promotion.
- Early traction included a 22% return customer rate in June, highlighting strong product-market fit and early brand loyalty.

Product Innovation & Brand Strengthening

- SystemLS selected for a large-scale U.S. clinical trial, validating product quality and science.
- Clean-label, plant-based focus continues to resonate with health-conscious consumers globally.
- Complementary product lines in development to expand the pipeline across immunity and personalised nutrition.





Improved Share Liquidity and Institutional Attention

- Share turnover rose to 209% of capital traded (vs. 84% prior year).
- Market cap increased to €3.7M as of June 30, 2025.
- Broader institutional attention reflects growing confidence in fundamentals.

Investor Confidence and Mission-Driven Outlook

Rapid Nutrition continues to be encouraged by the strong support from long-term shareholders, who share management's belief that sustainable, recurring revenue models build greater value over time. As one investor recently noted:

"The future of this company will be very strong. It takes time and significant investment to build financial stability — especially for a business committed to wellness and not just profits. For athletes and health-conscious consumers, the quality here is unmatched."

This perspective mirrors management's conviction that the transition to a subscription-driven DTC model is the most effective way to create long-term shareholder value. While near-term results reflect the deliberate move away from bulk sales, the predictable nature of subscriptions — already evidenced by strong customer uptake and expanding trade receivables — provides a foundation for stable, compounding growth.

Rapid Nutrition remains committed to building a globally respected wellness brand that leads with innovation, science, and trust. The Company will continue to prioritise **customer loyalty**, **product integrity**, **and sustainable financial growth**, ensuring that its long-term outlook remains aligned with both its mission and shareholder expectations.

Looking Ahead: Strong Second Half Expected

The Company enters H2 with:

- All major product manufacturing completed.
- Marketing budgets secured and optimised.
- Strong influencer partnerships already converting.
- Inventory strategically placed for key seasonal demand.

Management expects a significant uplift in sales performance in Q3 and Q4, driven by:

- Major consumer buying periods in Asia (e.g., Singles Day)
- Product line expansion into new SKUs
- Acceleration of new market distribution partnerships
- · Scaled-up direct response marketing and media spend

Conclusion

H1 was a period of building. H2 will be a period of scaling.

Rapid Nutrition remains focused on delivering innovation-led growth, international expansion, and shareholder value — while staying true to its mission of empowering consumers through clean, effective, and trustworthy wellness products.





Directors' responsibilities

The names and functions of the Directors of the Company are as follows:

Simon St Ledger	Chief Executive Officer
Shayne Kellow	Non-Executive Director
Jeffrey Reingold	Non-Executive Director
Michael Zhu	Chief Financial Officer

The Board confirms that to the best of its knowledge the condensed set of financial statements gives a true and fair view of the assets and liabilities, financial position and profit of the Group. The interim financial report is the responsibility of, and has been approved by, the directors. The directors are responsible for preparing the interim financial report in accordance with the Disclosure and Transparency Rules of the United Kingdom's Financial Conduct Authority. As disclosed in note 2, the statutory financial statements of the group are prepared in accordance with IFRSs as adopted by the European Union. The condensed set of consolidated financial statements included in this interim financial report has been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting", as adopted by the European Union.

Thank you for your time and support.

Sincerely,

Simon St. Ledger

Director

